Abstract：Cervical cancer is a common malignancy in women. Surgery and radiotherapy are the main therapeutic approaches. The recurrence rate of cervical cancer is high and the prognosis is relatively poor. Recurrent cervical cancer can be classified into the central pelvic, lateral pelvic and extra-pelvic recurrence. The management of recurrent cervical cancer mainly depends on previous therapeutic approaches and the recurrence site. Surgical resection is the optimal option for patients who have no history of radiotherapy, if feasible, chemoradiotherapy±brachytherapy can be considered. Patients with central pelvic recurrence after radiotherapy are suitable candidates for pelvic exenteration±intraoperative radiotherapy. However, the indications are highly selective, the incidence of postoperative complications is high and the quality of life is poor. Patients with lateral pelvic recurrence after radiotherapy could be treated by re-radiotherapy or chemotherapy. However, the incidence of serious side effects of re-radiotherapy is higher than that of the initial radiotherapy. The indications for stereotactic body radiotherapy are limited and the surgical skill of the surgeons is demanding. In recent years, radiotherapy technology has become more precise. Image-guided brachytherapy, such as high-dose-rate interstitial brachytherapy and radioactive 125I seed implantation, has achieved high efficacy and safety, which may provide new treatment options for recurrent cervical cancer. In this article, research progress on brachytherapy for recurrent cervical cancer was summarized and reviewed.
Liu Yanhao,Wang Junjie. Research progress on brachytherapy for recurrent cervical cancer[J]. Chinese Journal of Radiation Oncology, 2021, 30(3): 297-300.
[1] Cohen PA,Jhingran A,Oaknin A,et al.Cervical cancer[J].Lancet,2019,393(10167):169-182.DOI:10.1016/S0140-6736(18)32470-X. [2] Koh WJ,Abu-Rustum NR,Bean S,et al.Cervical cancer,version 3.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(1):64-84.DOI:10.6004/jnccn.2019.0001. [3] Pfaendler KS,Tewari KS.Changing paradigms in the systemic treatment of advanced cervical cancer[J].Am J Obstet Gynecol,2016,214(1):22-30.DOI:10.1016/j.ajog.2015.07.022. [4] Peiretti M,Zapardiel I,Zanagnolo V,et al.Management of recurrent cervical cancer:a review of the literature[J].Surg Oncol,2012,21(2):e59-66.DOI:10.1016/j.suronc.2011.12.008. [5] Boussios S,Seraj E,Zarkavelis G,et al.Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:where do we stand? A literature review[J].Crit Rev Oncol Hematol,2016,108:164-174.DOI:10.1016/j.critrevonc.2016.11.006. [6] Kim HJ,Chang JS,Koom WS,et al.Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer[J].Gynecol Oncol,2018,151(2):208-214.DOI:10.1016/j.ygyno.2018.08.029. [7] Höckel M,Dornhöfer N.Pelvic exenteration for gynaecological tumours:achievements and unanswered questions[J].Lancet Oncol,2006,7(10):837-847.DOI:10.1016/S1470-2045(06)70903-2. [8] 邓浩,王建六.盆腔廓清术在复发性妇科恶性肿瘤治疗中的应用进展[J].中国计划生育和妇产科,2019,11(10):20-23+29.DOI:10.3969/j.issn.1674-4020.2019.10.06. Deng H,Wang JL.Progress of pelvic clearance in the treatment of recurrent gynecological carcinomas[J].Chin J Family Plan Gynecotokol,2019,11(10):20-23,29.DOI:10.3969/j.issn.1674-4020.2019.10.06. [9] Onal C,Gultekin M,Oymak E,et al.Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies:a multi-institutional analysis[J].Int J Gynecol Cancer,2020,30(6):865-872.DOI:10.1136/ijgc-2019-001115. [10] Abusaris H,Hoogeman M,Nuyttens JJ.Re-irradiation:outcome,cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region[J].Technol Cancer Res Treat,2012,11(6):591-597.DOI:10.7785/tcrt.2012.500261. [11] Seo Y,Kim MS,Yoo HJ,et al.Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall:feasibility and complication[J].Asia Pac J Clin Oncol,2016,12(2):e280-288.DOI:10.1111/ajco.12185. [12] 江萍,张福泉,程光惠,等.复发宫颈癌近距离治疗专家共识[J].中华放射肿瘤学杂志,2020,29(9):721-729.DOI:10.3760/cma.j.cn113030-20200409-00170. Jiang P,Zhang FQ,Cheng GH,et al.Expert consensus on brachytherapy for recurrent cervical cancer[J].Chin J Radiat Oncol,2020,29(9):721-729.DOI:10.1111/ajco.12185. [13] Weitmann HD,Knocke TH,Waldhäusl C,et al.Ultrasound-guided interstitial brachytherapy in the treatment of advanced vaginal recurrences from cervical and endometrial carcinoma[J].Strahlenther Onkol,2006,182(2):86-95.DOI:10.1007/s00066-006-1420-4. [14] Mabuchi S,Takahashi R,Isohashi F,et al.Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer:a single institutional experience[J].Int J Gynecol Cancer,2014,24(1):141-148.DOI:10.1097/IGC.0000000000000028. [15] Mahantshetty U,Kalyani N,Engineer R,et al.Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix[J].Brachytherapy,2014,13(6):548-553.DOI:10.1016/j.brachy.2014.06.005. [16] Zolciak-Siwinska A,Bijok M,Jonska-Gmyrek J,et al.HDR brachytherapy for the reirradiation of cervical and vaginal cancer:analysis of efficacy and dosage delivered to organs at risk[J].Gynecol Oncol,2014,132(1):93-97.DOI:10.1016/j.ygyno.2013.10.018. [17] Umezawa R,Murakami N,Nakamura S,et al.Image-guided interstitial high-dose-rate brachytherapy for locally recurrent uterine cervical cancer:a single-institution study[J].Brachytherapy,2018,17(2):368-376.DOI:10.1016/j.brachy.2017.11.011. [18] Kozai Y,Itoh Y,Kawamura M,et al.High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy[J].Nagoya J Med Sci,2019,81(3):351-358.DOI:10.18999/nagjms.81.3.351. [19] Chopra S,Engineer R,Shah S,et al.MRI-and PET-guided interstitial brachytherapy for postsurgical vaginal recurrences of cervical cancer:results of phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,2020,106(2):310-319.DOI:10.1016/j.ijrobp.2019.10.037. [20] Chopra S,Dora T,Engineer R,et al.Late rectal toxicity after image-based high-dose-rate interstitial brachytherapy for postoperative recurrent and/or residual cervical cancers:EQD2 predictors for Grade ≥Ⅱ toxicity[J].Brachytherapy,2015,14(6):881-888.DOI:10.1016/j.brachy.2015.08.007. [21] Qu A,Jiang P,Sun H,et al.Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy[J].J Gynecol Oncol,2018,30(1):e9.DOI:10.3802/jgo.2019.30.e9. [22] 王皓,王俊杰,袁慧书,等.CT引导125I粒子植入治疗局部复发直肠癌疗效和剂量学分析[J].中华放射肿瘤学杂志,2016,25(10):1096-1099.DOI:10.3760/cma.j.issn.1004-4221.2016.10.016. Wang H,Wang JJ,Yuan HS,et al.Efficacy and dosimetry of computed tomography image-guided 125I radioactive seed implantation for locally recurrent rectal cancer[J].Chin J Radiat Oncol,2016,25(10):1096-1099.DOI:10.3760/cma.j.issn.1004-4221.2016.10.016. [23] Ji Z,Jiang Y,Tian S,et al.The effectiveness and prognostic factors of CT-guided radioactive I-125 seed implantation for the treatment of recurrent head and neck cancer after external beam radiation therapy[J].Int J Radiat Oncol Biol Phys,2019,103(3):638-645.DOI:10.1016/j.ijrobp.2018.10.034. [24] 彭冉,姜玉良,吉喆,等.放射性粒子植入的生物有效剂量计算及其临床应用[J].中华放射医学与防护杂志,2017,37(7):522-527.DOI:10.3760/cma.j.issn.0254-5098.2017.07.010. Peng R,Jiang YL,Ji Z,et al.Biologically effective dose calculation of radioactive seed implantation brachytherapy and its clinical application[J].Chin J Radiol Prot,2017,37(7):522-527.DOI:10.3760/cma.j.issn.0254-5098.2017.07.010. [25] 李俊勇,王巍.CT引导下放射性125I粒子组织间植入治疗复发宫颈癌的疗效观察[J].科技导报,2009,27(7):29-31.DOI:10.3321/j.issn:1000-7857.2009.07.006. Li JY,Wang W.Treatment of recurrent cervix malignancies with iodine-125 permanent interstitial tissue implantation guided by CT[J].Sci Technol Rev,2009,27(7):29-31.DOI:10.3321/j.issn:1000-7857.2009.07.006. [26] 王俊杰.3D打印技术在精准粒子植入治疗中的应用[J].中华放射医学与防护杂志,2017,37(7):481-484.DOI:10.3760/cma.j.issn.0254-5098.2017.07.001.Wang JJ.Application of 3D-printing in accurate seed implantation therapy[J].Chin J Radiol Protect,2017,37(7):481-484.DOI:10.3760/cma.j.issn.0254-5098.2017.07.001. [27] 姜玉良,王皓,吉喆,等.CT引导辅助3D打印个体化非共面模板指导125I粒子治疗盆腔复发肿瘤剂量学研究[J].中华放射肿瘤学杂志,2016,25(9):959-964.DOI:10.3760/cma.j.issn.1004-4221.2016.09.012. Jiang YL,Wang H,Ji Z,et al.Computed tomography image-guided and personalized 3D printed template-assisted 125-iodine seed implantation for recurrent pelvic tumor:a dosimetric study[J].Chin J Radiat Oncol,2016,25(9):959-964.DOI:10.3760/cma.j.issn.1004-4221.2016.09.012.
2021, Vol. 30 
